Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis [8]

Emerging Infectious Diseases

Volumn 14, Issue 2, 2008, Pages 349-350

  Tazi, Asmaa ^a,b,c   Gueudet, Thomas ^d   Varon, Emanuelle ^a   Gilly, Liliane ^c   Trieu Cuot, Patrick ^a,e   Poyart, Claire ^a,b,c,e,f  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Laboratoire Schuh Biosphere   (France)

^e INSTITUT PASTEUR   (France)

^f Centre National de Référence des Streptocoques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RIFAMPICIN; SPARFLOXACIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; DISEASE EXACERBATION; DNA SEQUENCE; EPITHELIUM CELL; FRANCE; HUMAN; LETTER; LEUKOCYTE COUNT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION;

EID: 38949177054     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1402.071006     Document Type: Letter

References (10)

1. Blasi F, Ewig S, Torres A, Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther. 2006;19:361-9.
2. Schuchat A. Group B streptococcus. Lancet. 1999;353:51-6.
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S17. Wayne (PA): The Institute; 2007.
4. Hooper DC. Fluoroquinolone resistance among gram-positive cocci. Lancet Infect Dis. 2002;2:530-8.
5. Houssaye S, Gutmann L, Varon E. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46:2712-5.
6. Kawamura Y, Fujiwara H, Mishima N, Tanaka Y, Tanimoto A, Ikawa S, et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother. 2003;47:3605-9.
7. Miro E, Rebollo M, Rivera A, Alvarez MT, Navarro F, Mirelis B, et al. Streptococcus agalactiae highly resistant to fluoroquinolones. Enferm Infecc Microbiol Clin. 2006;24:562-3.
8. Wehbeh W, Rojas-Diaz R, Li X, Mariano N, Grenner L, Segal-Maurer S, et al. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother. 2005;49:2495-7.
9. Perez-Trallero E, Marimon JM, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis. 2005;41:560-4.
10. Hayes D, Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. Drugs Aging. 2007;24:555-72.